Patents Examined by Galina Yakovleva
  • Patent number: 9863966
    Abstract: The invention provides novel haptens and immunogens for the preparation of novel monoclonal antibodies, which detect the synthetic opioid meperidine and its active metabolite normeperidine. These antibodies enable methods and kits, which are useful in an immunoassay for therapeutic drug monitoring (TDM) and in extending the window of detection for cases of abuse and drug-facilitated sexual assault (DFSA).
    Type: Grant
    Filed: October 8, 2013
    Date of Patent: January 9, 2018
    Assignee: Randox Laboratories Limited
    Inventors: Ivan McConnell, Elouard Benchikh, Philip Lowry, Peter Fitzgerald
  • Patent number: 9851309
    Abstract: Provided is a ultra-high-sensitivity assay in which the assay can be made on a commonly used assay apparatus such as an absorptiometer and a plate reader or with naked eyes. The high-sensitivity assay in which the assay can be made on a commonly used assay apparatus or with naked eyes can be provided by combining an enzyme cycling method using thio-NAD(P) as a coenzyme, a labeling enzyme and a substrate for the labeling enzyme optimally, and by amplifying thio-NAD(P)H, which is a signaling substance, exponentially and then quantifying the thio-NAD(P)H colorimetrically.
    Type: Grant
    Filed: March 23, 2012
    Date of Patent: December 26, 2017
    Inventor: Etsuro Ito
  • Patent number: 9846161
    Abstract: A novel quantum dot capable of near infrared emissions at wavelengths of 750-1100 is made by forming solid solutions of metal sulfide, metal selenide or metal sulfide selenide by incorporating a suitable amount of an additional metallic element or elements to provide an emission wavelength in the range of 750 nm to 1100 nm. The quantum dots may be enabled for bioconjugation and may be used in a method for tissue imaging and analyte detection.
    Type: Grant
    Filed: September 12, 2014
    Date of Patent: December 19, 2017
    Assignee: DREXEL UNIVERSITY
    Inventors: Wei-Heng Shih, Wan Y. Shih, Hui Li, Ian McDonald, Andrew Kopek, Ryan O'Malley, Yu-Chieh Lu
  • Patent number: 9835629
    Abstract: Methods and sets of non-biological reagents (elution reagents, tag isomers, tag reactive groups, crosslinkers) for single or multiplexed capture and gentle elution of biomolecules. Examples are provided using amine- and cysteine-reactive reagents for enrichment of proteins, peptides, and rare peptide modifications.
    Type: Grant
    Filed: March 11, 2013
    Date of Patent: December 5, 2017
    Assignee: Pierce Biotechnology, Inc.
    Inventors: John Charles Rogers, Ryan Daniel Bomgarden, Christopher Laurence Etienne, Eric Leigh Hommema
  • Patent number: 9802981
    Abstract: The invention relates to methods for effecting qualitative and quantitative changes in the functional moieties expressed at the surface of cells and multi-cellular structures, and functional lipid constructs for use in such methods. In particular, the invention relates to functional lipid constructs and their use in diagnostic and therapeutic applications, including serodiagnosis, where the functional moiety is a carbohydrate, peptide, chemically reactive group, conjugator or fluorophore.
    Type: Grant
    Filed: February 4, 2014
    Date of Patent: October 31, 2017
    Assignee: Kode Biotech Limited
    Inventors: Nicolai Vladimirovich Bovin, Stephen Micheal Henry, Igor Leonidovich Rodionov, Cristina-Simona Weinberg, Alexander Borisovich Tuzikov
  • Patent number: 9797886
    Abstract: The purpose of the present invention is to provide an agglutination enhancer which shows superior agglutination enhancing effect to those of conventional immunoagglutination enhancers, and the present invention relates to an agglutination enhancer for an immunoagglutination measurement method which comprises a polymer having a monomer unit shown by the following general formula [1]: (Wherein R1 represents a hydrogen atom or a methyl group; R2 and R3 independently represent a methyl group or an ethyl group, respectively; X represents —NH— or an oxygen atom; n represents an integer of 1 to 6; and m represents an integer of 1 to 3), and an immunoagglutination measurement method in which, in the coexistence of the above-described agglutination enhancer for immunoagglutination measurement method, an antibody against analyte or an antigen for the analyte is brought into contact with the analyte to cause an antigen-antibody reaction.
    Type: Grant
    Filed: June 4, 2012
    Date of Patent: October 24, 2017
    Assignee: Wako Pure Chemical Industries, Ltd.
    Inventors: Naoyuki Yamamoto, Tsutomu Masuda
  • Patent number: 9797897
    Abstract: Acoustically responsive particles and methods are provided for their use. Methods are provided for making and using tunable, monodisperse acoustically responsive particles and negative contrast acoustic particles, wherein the particles can contain a functional group available for covalent modification.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: October 24, 2017
    Assignee: DUKE UNIVERSITY
    Inventors: Leah M. Johnson, Gabriel P. Lopez, Lu Gao, Charles Wyatt Shields, IV
  • Patent number: 9784752
    Abstract: The invention describes antibodies that bind venlafaxine and O-desmethylvenlafaxine. The antibodies are derived from novel haptens and immunogens and are used in methods and kits to detect and quantify venlafaxine and O-desmethylvenlafaxine. The invention also describes novel detecting agents which can be used in the methods and kits of the invention.
    Type: Grant
    Filed: April 11, 2013
    Date of Patent: October 10, 2017
    Assignee: Randox Laboratories Limited
    Inventors: Elouard Benchikh, Ivan McConnell, Philip Lowry, Peter Fitzgerald
  • Patent number: 9784734
    Abstract: Systems include test cells with sorbent material in a T-shape and defining a first flow path for a solution and a second flow path for a sample, and a test line or test site with immobilized antigens or antibodies or other ligand binding molecules located at the junction of the T. A housing houses the sorbent material and defines a first hole adjacent an end of the first flow path for receiving the solution and a second hole adjacent an end of the second flow path for receiving the sample.
    Type: Grant
    Filed: November 4, 2014
    Date of Patent: October 10, 2017
    Assignee: CHEMBIO DIAGNOSTIC SYSTEMS, INC.
    Inventor: Javanbakhsh Esfandiari
  • Patent number: 9777069
    Abstract: Methods and reagents are disclosed for conducting assays for EDDP. The reagents include a moiety selected from the group consisting of poly(amino acid) label moieties, non-poly(amino acid) label moieties, poly(amino acid) immunogenic carriers, non-poly(amino acid) immunogenic carriers, non-label poly(amino acid) moieties, and non-immunogenic carrier poly(amino acid) moieties linked to 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine at the 3-position of one of the phenyl rings. Antibodies produced from immunogenic EDDP conjugates and labeled EDDP conjugates are employed in assays for determining the presence and/or amount of EDDP in samples suspected of containing EDDP.
    Type: Grant
    Filed: April 4, 2014
    Date of Patent: October 3, 2017
    Assignee: Siemens Healthcare Diagnostics Inc.
    Inventor: Bhalchandra Lele
  • Patent number: 9746483
    Abstract: The invention concerns a process for the production of a hybridoma, and of a monoclonal antibody or fragments thereof able to recognize 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3.
    Type: Grant
    Filed: May 11, 2015
    Date of Patent: August 29, 2017
    Assignee: DIASOURCE IMMUNOASSAYS S.A.
    Inventors: Michel Anciaux, Fabienne Mathieu, Frederic Lin, Martin Poncelet
  • Patent number: 9745339
    Abstract: The present invention relates to the use, for affinity purification of an antibody or an fragment of an antibody, of a ligand-substituted matrix comprising a support material and at least one ligand covalently bonded to the support material, the ligand being represented by formula (I) L-(Sp)v-Ar1—Am—Ar2?? (I) wherein L, SP, Ar1, AM, Ar2 and v are defined herein.
    Type: Grant
    Filed: February 8, 2013
    Date of Patent: August 29, 2017
    Assignee: NOVALIX DEUTSCHLAND GMBH
    Inventors: Holger Bittermann, Marc Arnold, Thomas Neumann, Inge Ott, Kristina Schmidt, Renate Sekul
  • Patent number: 9702869
    Abstract: The present invention relates to conjugates of 5-fluorouracil, 5-fluorouracil immunogens, antibodies that bind 5-FU and/or 5-FU conjugated to another molecule, and assays for detecting, quantitating, and monitoring amounts of 5-fluorouracil in a sample such as in blood plasma.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: July 11, 2017
    Assignee: DEFINED DIAGNOSTICS, LLC
    Inventors: Paul Q Hu, Xiaofen Huang, Reid W Von Borstel
  • Patent number: 9688743
    Abstract: Provided are biosensors, compositions comprising biosensors, and methods of using biosensors in living cells and organisms. The biosensors are able to be selectively targeted to certain regions or structures within a cell. The biosensors may provide a signal when the biosensor is targeted and/or in response to a property of the cell or organism such as membrane potential, ion concentration or enzyme activity.
    Type: Grant
    Filed: January 2, 2014
    Date of Patent: June 27, 2017
    Assignee: CARNEGIE MELLON UNIVERSITY
    Inventors: Brigitte F. Schmidt, Christopher S. Szent-Gyorgyi, Alan S. Waggoner, Peter B. Berget, Marcel P. Bruchez, Jonathan W. Jarvik
  • Patent number: 9671415
    Abstract: The current invention provides an improved immunoassay for the detection and determination of pyrrolidinophenone based designer drugs in hair and biological fluids (urine, blood, and oral fluid). The generic immunoassay is underpinned by novel, sub-family-specific antibodies, which display surprising sensitivity. The invention further describes substrates comprising an antibody that is specific to compounds of the pyrrolidinophenone family. Also described are the novel immunogens from which the antibodies are derived and kits incorporating the antibodies of the current invention.
    Type: Grant
    Filed: October 2, 2015
    Date of Patent: June 6, 2017
    Assignee: Randox Laboratories Limited
    Inventors: Ivan McConnell, Peter Fitzgerald, Philip Lowry, Elouard Benchikh
  • Patent number: 9612237
    Abstract: The invention provides novel antibodies which specifically bind to the methylphenidate metabolite, ritalinic acid, enabling an immunoassay that can detect methylphenidate in biological samples for an extended period following its ingestion. The invention also describes novel conjugates and kits incorporating the antibodies.
    Type: Grant
    Filed: February 21, 2014
    Date of Patent: April 4, 2017
    Assignee: Randox Laboratories Limited
    Inventors: Philip Lowry, Elouard Benchikh, Ivan McConnell, Peter Fitzgerald
  • Patent number: 9592501
    Abstract: A microfluidic structure comprising a thermoplastic portion defining a microfluidic recess, a bonding layer on the thermoplastic portion and a siloxane elastomer portion covalently bonded to the bonding layer to seal the microfluidic recess. The microfluidic recess can therefore be formed simply, quickly and cheaply using known injection molding techniques, which are not hampered by the need for a curing step. However, the positive qualities associated with elastomers can be brought to the structure by using this to seal the microchannels. The bonding layer can be formed by silica deposited on the thermoplastic portion using techniques known in the field of optics.
    Type: Grant
    Filed: December 9, 2015
    Date of Patent: March 14, 2017
    Assignee: LANDEGREN GENE TECHNOLOGY AB
    Inventors: Jonas Sven Peter Jarvius, Jonas Melin
  • Patent number: 9581594
    Abstract: Porphyrin-modified antimicrobial peptides as described here may be used as indicators of the presence of microbial targets. Their application may be as (for example) (1) fluorescent indicators in a microarray format, (2) fluorescence or absorbance based indicators in traditional solution based applications, or (3) reflectance based indicators for use in reagent-less detection platforms.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: February 28, 2017
    Assignee: The United States of America, as represented by the Secretary of the Navy
    Inventors: Chris Rowe Taitt, Brandy J. White
  • Patent number: 9551705
    Abstract: The present invention provides compositions and methods for capture and identification of the cellular targets of a bioactive agent. In particular, provided herein are bioactive agents tethered to capture ligand, cellular targets (optionally tagged with a reporter), capture proteins (optionally present as capture fusions), surfaces (e.g., displaying, capture ligands, capture proteins, or capture fusions), and methods of capturing and identifying the cellular targets of a bioactive agent therewith.
    Type: Grant
    Filed: December 12, 2013
    Date of Patent: January 24, 2017
    Assignee: Promega Corporation
    Inventors: Carolyn W. Hitko, Robin Hurst, Thomas Kirkland, Dieter Klaubert, Poncho Meisenheimer, Nidhi Nath, Rachel Friedman Ohana, Paul Otto, Marjeta Urh, Harry Tetsuo Uyeda, Keith Wood, Ji Zhu
  • Patent number: 9547016
    Abstract: The present invention relates to a method for determining the amount of a physiologically acceptable polymer molecule bound to a protein, an antibody or other composition being capable of specifically binding to a physiologically acceptable polymer molecule, and a kit containing said antibody or composition.
    Type: Grant
    Filed: September 13, 2013
    Date of Patent: January 17, 2017
    Assignees: Baxalta Incorporated, Baxalta GmbH
    Inventors: Peter Turecek, Juergen Siekmann, Alfred Weber, Herbert Gritsch, Katalin Varadi, Susanne Vejda